Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insurers back Prilosec OTC

This article was originally published in The Tan Sheet

Executive Summary

Humana joins list of insurers offering coupons for switch drug, firm announces Sept. 25. Members that "take prescription medication for chronic heartburn" will be mailed coupon for free 14-count package. Separately, North Carolina Blue Cross/Blue Shield sending more than 40,000 coupons provided by P&G for $10 off retail to "frequent sufferers of intermittent heartburn." Insurer drops Rx Prilosec, omeprazole coverage, shifts follow-on prescription PPI Nexium to higher co-pay tier. Moves follow similar action by WellPoint (1"The Tan Sheet" Sept. 15, 2003, p.3)...

You may also be interested in...



Omeprazole, Ibuprofen Among OTCs Listed On Medicare Rx Price Website

The new Medicare prescription drug price comparison 1website includes information on a handful of OTC-strength products including omeprazole 20 mg (Prilosec OTC)

J&J/Merck Challenge Prilosec OTC Claims; Insurer Incentives Support Launch

Johnson & Johnson/Merck is contesting claims made in a television spot for P&G's Prilosec OTC that one pill can provide relief for 24 hours

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel